

2. As used in this Consent Judgment, (i) the term “InnoPharma Product” shall mean a drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 208648 (and defined in greater detail in the Settlement Agreement); and (ii) the

term “Affiliate” shall mean, with respect to a Party, any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, “control” means (a) ownership, directly or through one or more intermediaries, of (i) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (ii) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the board of directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity.

3. Unless otherwise specifically authorized pursuant to the Settlement Agreement, InnoPharma, including any of its Affiliates, successors and assigns, is enjoined from infringing United States Patent Numbers 6,774,122, 7,456,160, 8,329,680 and 8,466,139, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the InnoPharma Product.

4. Compliance with this Consent Judgment may be enforced by AstraZeneca and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

5. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys’ fees to any party.

A handwritten signature in black ink, appearing to read "Renee M. Bumb", is written over a horizontal line.

Renee M. Bumb, U.S.D.J.

We hereby consent to the form and entry of this Order:

s/John E. Flaherty

Lisa B. Pensabene
Filko Prugo
Will C. Autz
O'MELVENY & MYERS LLP
Times Square Tower
7 Times Square
New York, NY 10036
(212) 326-4481

John Edmund Flaherty
Ravin R. Patel
MCCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, NJ 07102
(973) 622-4444

*Attorneys for AstraZeneca AB, AstraZeneca
UK Limited, and AstraZeneca Pharmaceuticals
LP*

s/Karen A. Confoy

Mark. A. Pacella
Karin A. Hessler
Wesley Weeks
WILEY REIN, LLP
1776 K Street NW
Washington, DC 20006
(202) 719-7000

Karen A. Confoy
Christopher R. Kinkade
FOX ROTHSCHILD LLP
997 Lenox Drive Bldg 3
Lawrenceville, NJ 08648
(609) 844-3033

Attorneys for InnoPharma Licensing LLC